Parenteral formulations comprising uracil derivatives

TW202639131APending Publication Date: 2026-10-01SHIONOGI & CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114147894
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-04
Filing Date
2025-12-08
Publication Date
2026-10-01

Smart Images

  • Figure TWG2TA001078709_001
    Figure TWG2TA001078709_001
  • Figure TWG2TA001078709_002
    Figure TWG2TA001078709_002
  • Figure TWG2TA001078709_003
    Figure TWG2TA001078709_003
Patent Text Reader

Abstract

This invention relates to a non-oral formulation containing a uracil derivative. This invention relates to a sustained-release formulation containing a uracil derivative. More specifically, it relates to a non-oral formulation comprising a suspension of a uracil derivative exhibiting inhibitory activity against coronavirus 3CL protease. More specifically, it relates to a formulation for subcutaneous, intradermal, or intramuscular injection comprising a suspension of a uracil derivative exhibiting inhibitory activity against coronavirus 3CL protease.
Need to check novelty before this filing date? Find Prior Art